STX-0712

STX-0712 showed robust activity against CCR2-positive monocytes in CMML and AML patient samples BOSTON, mA, USA I December 9, 2024 I Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced positive preclinical data on STX-0712, its novel CCR2-CyTAC ™ (Cytotoxicity Targeting Chimera), for the treatment of chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). Results were presented over the weekend in two poster sessions at the American Society of Hematology (ASH) Annual Meeting, held December 7-10, 2024, in San Diego, California. “The encouraging results from our preclinical studies in CMML and AML highlight the unique power of our CyTAC platform to precisely target and eliminate disease-driving cells,” said Sergio Santillana, Chief Medical Officer of Solu. “STX-0712’s ability to selectively target CCR2-positive malignant monocytes in these two challenging blood cancers showcases the platform’s potential to support the development of transformative treatments for different types of cancer and other diseases. We look forward to advancing STX-0712 into clinical trials and continuing to leverage our platform for other high-need diseases.” Preclinical Results for STX-0712 in CMML Key Findings : To access the full abstract, click here . Preclinical Results for STX-0712 in AML Key Findings : To access the full abstract, click here . “The results from these studies represent a significant milestone for Solu, as they reinforce the potential of STX-0712 in the treatment CMML and AML, two diseases with limited targeted therapies available,” said Brandon Turunen, Co-founder, Chief Technology Officer, and Head of Drug Discovery at Solu. “By targeting the underlying drivers of these diseases, STX-0712 could offer a highly targeted approach to treatment while maintaining a strong safety profile. We look forward to advancing this promising program to clinical-stage research in 2025.” About STX-0712 STX-0712 is a CyTAC targeting the G-Protein Coupled Receptor (GPCR) CCR2, a selective marker expressed at high levels on malignant monocytes that are key drivers in certain hematologic cancers. By targeting CCR2, STX-0712 is designed to selectively eliminate these malignant cells. About Solu Therapeutics Solu Therapeutics is a biotechnology company dedicated to developing next-generation therapeutics to eliminate disease-driving cells in cancer, immunology and other therapeutic areas. The company’s proprietary CyTAC (Cytotoxicity Targeting Chimera) and TicTAC™ (Therapeutic Index Control Targeting Chimera) platforms enable the development of innovative medicines that combine the target-binding capability of small molecules with the therapeutic power of biologics. Solu Therapeutics is committed to advancing the field of oncology, immunology and other therapeutic areas by bringing transformative therapies to patients in need. SOURCE: Solu Therapeutics